NEW YORK, June 29, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Apyx Medical Corporation (NASDAQ: APYX) between May 12, 2021 and March 11, 2022, both dates inclusive (the “Class Period”), of the important August 5, 2022 lead plaintiff deadline.
SO WHAT: If you purchased Apyx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Apyx class action, go to https://rosenlegal.com/submit-form/?case_id=6835 or call

The Chemours Company (NYSE:CC – Get Rating) SVP Matthew S. Abbott sold 8,912 shares of the firm’s stock in a transaction dated Thursday, June 8th. The stock was sold at an average price of $34.20, for a total value of $304,790.40. Following the completion of the transaction, the senior vice president now owns 29,869 shares of the company’s stock, valued at approximately $1,021,519.80. The sale was disclosed in a document filed with the SEC, which can be accessed via the SEC website.